XXV REUNIÓN

INSUFICIENCIA CARDIACA Y FIBRILACIÓN AURICULAR

4 y 5 mayo | Palacio de Congresos

2023 | Girona

#25ICyFA

CORAZÓN Y RIÑÓN

Jesús Casado
Hospital Universitario de Getafe


ø30
25
25
17
ø63
25
25
2
32
25
98
49
14x45°
4 фаски
ø13
4 отв
14
ø60
25



FALLO ANTERÓGRADO BAJO GASTO

Disminución perfusión arteriola aferente

Activación SRAA

FALLO RETRÓGRADO AUMENTO PRESIÓN VENOSA

Aumento de presión cápsula de Bowman

Hipoxia tubular



DISMINUCIÓN FILTRADO GLOMERULAR

Journal of the American College of Cardiology
© 2009 by the American College of Cardiology Foundation
Published by Elsevier Inc.

Vol. 53, No. 7, 2009
ISSN 0735-1097/09/$36.00
doi:10.1016/j.jacc.2008.05.068

Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure

Wilfried Mullens, MD, Zuheir Abrahams, MD, PHD, Gary S. Francis, MD, FACC, George Sokos, DO, David O. Taylor, MD, FACC, Randall C. Starling, MD, MPH, FACC, James B. Young, MD, FACC, W. H. Wilson Tang, MD, FACC

Cleveland, Ohio

NEFROPATÍA CONGESTIVA



Husain-Syed F et al. Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. ESC Heart Fail. 2021 Feb;8(1):183-203



Renal Compression in Heart Failure

The Renal Tamponade Hypothesis



Boorsma, E.M. et al. J Am Coll Cardiol HF. 2022



	Agudo	Crónico
Cardiorrenal	 SCR Tipo I	 SCR Tipo II
Renocardiaco	 SCR Tipo III	 SCR Tipo IV

	Agudo	Crónico
Cardiorrenal	SCR Tipo I	 SCR Tipo II
Renocardiaco	 SCR Tipo III	SCR Tipo IV

Albuminuria and Heart Failure

JACC State-of-the-Art Review

CENTRAL ILLUSTRATION Albuminuria as a Risk Marker for Heart Failure



Khan MS, et al. J Am Coll Cardiol. 2023;81(3):270-282.

	Agudo	Crónico
Cardiorrenal	 SCR Tipo I	SCR Tipo II
Renocardiaco	 SCR Tipo III	 SCR Tipo IV





Damman; Eur Heart J 2015; doi:10.1093/eurheartj/ehv010

Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?

The Role of Congestion and Its Interaction With Renal Function

Marco Metra, MD; Beth Davison, PhD; Luca Bettari, MD; Hengrui Sun, MD; Christopher Edwards, BS; Valentina Lazzarini, MD; Barbara Piovanelli, MD; Valentina Carubelli, MD; Silvia Bugatti, MD; Carlo Lombardi, MD; Gad Cotter, MD; Livio Dei Cas, MD




iSGLT2
Evidence
Strong
Moderate
Weak
Absent
ACEi / Beta-Blocker / MRA / ARB / ICD / CRT
ACEi / Beta-Blocker / MRA / ICD / CRT
Ivabradine
Ivabradine / ARB
Beta-Blocker
Digoxin / H-ISDN
Digoxin / H-ISDN
ACEi / ARB / Digoxin / ICD
Diuretics
Diuretics
MRA / CRT Ivabradine / H-ISDN / Diuretics
Risk of WRF/Hyperkalemia/Mortality
CKD stage
Stage 1 or normal
Stage 2
Stage 3
Stage 4
Stage 5
≥ 120
90
60
30
15
ESRD
Glomerular Filtration Rate (mL/min/1.73²)

ESC European Society of Cardiology
European Journal of Heart Failure (2022)
doi:10.1002/ejhf.2471
POSITION PAPE

Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology



Key messages

1. Acute drop in GFR with RAASi, ARNI and SGLT2-i does not diminishes treatment effect
2. A reduction in slope deterioration in HFrEF with ARNI and SGLT2-i is associated with reduced hard renal endpoints

Mullens et al. European Journal of Heart Failure (2022) 24, 603–619

ESC European Society of Cardiology
European Journal of Heart Failure (2022)
doi:10.1002/ejhf.2471
POSITION PAPE

Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology



Mullens et al. European Journal of Heart Failure (2022) 24, 603–619

Muchas gracias